Skip to main content
. 2015 Apr 1;35(13):5271–5283. doi: 10.1523/JNEUROSCI.0650-14.2015

Figure 3.

Figure 3.

LRRK2 kinase inhibition reduces p38 and JNK signaling in Tat-treated primary microglia. Western blot of pp38, p54 pJNK, p46 pJNK, and β-actin protein levels 30 min (A) and 6 h (E) after saline (Sa) or Tat treatment with or without LRRK2-IN-1 (IN-1) and GSK2578215A (GSK). B–D, GSK2578215A, but not LRRK2-IN-1, significantly inhibits Tat-induced pp38, p54 pJNK, and p46 pJNK 30 min after treatment. F–H, LRRK2-IN-1 and GSK2578215A significantly inhibit Tat-induced pp38 6 h after treatment, but no change in p54 pJNK or p46 pJNK is observed (***p < 0.01, one-way ANOVA with Newman–Keuls post hoc test).